+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression

Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression

Canadian Journal of Gastroenterology 14 Suppl D: 11d

Until now, oral proton pump inhibitors have not been available as parenteral therapy in the acute care setting. Pantoprazole is the first parenteral proton pump inhibitor to become available in Canada. This agent is superior to the parenteral histamine 2 receptor antagonists with respect to acid suppressive effects and is not associated with tolerance development. Another advantage over the histamine 2 receptor antagonists is that pantoprazole does not require dosage adjustment in patients with renal impairment. Dosage adjustments are also not required for elderly patients or those with hepatic impairment when the drug is used at the usual dose for a limited period of time. Contrary to intravenous cimetidine and ranitidine, which have negative inotropic and chronotropic effects, intravenous pantoprazole is well tolerated and has no significant effect on heart rate, contractility or blood pressure. The lack of drug interactions for this agent also simplifies its use, especially in patients who may require multiple drugs during hospitalization. Parenteral pantoprazole is effective in the treatment of reflux esophagitis. It is also promising for the treatment of upper gastrointestinal bleeding and in the perioperative care of patients with Zollinger-Ellison syndrome, but further research in these areas is necessary. Once the patient is able to tolerate oral medications, parenteral therapy can be easily converted to oral therapy using an oral dose that was equivalent to the parenteral dose (ie, 40 mg given intravenously is equivalent to 40 mg given orally).

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046458746

Download citation: RISBibTeXText

PMID: 11110607

Related references

Maximal acid suppression Oral vs intravenous pantoprazole. Gastroenterology 122(4 Suppl 1): A-476-A-477, 2002

Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepato-Gastroenterology 46(27): 1809-1815, 1999

The comparison of extemporaneous preparations of omeprazole, pantoprazole oral suspension and intravenous pantoprazole on the gastric pH of critically ill-patients. Indian Journal of Critical Care Medicine 19(1): 21-26, 2015

Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Canadian Journal of Gastroenterology 15(12): 795-798, 2001

Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. Journal of Gastroenterology and Hepatology 22(9): 1429-1434, 2007

Intravenous pantoprazole rapidly and effectively controls acid output in patients with Zollinger-Ellison Syndrome. Gastroenterology 114(4 Part 2): A226, 1998

Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118(4): 696-704, 2000

Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients. Nephrology 17(5): 458-465, 2012

Esomeprazole 40 mg intravenous provides faster and more effective acid control than pantoprazole 40 mg intravenous after first dose and 5 days. American Journal of Gastroenterology 98(9 Suppl.): S24-S25, 2003

Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study. Nephrology 17(4): 402-406, 2012

Zollinger-Ellison syndrome patients can replace oral proton pump inhibitors with intravenous pantoprazole without losing control of acid output. Gastroenterology 116(4 Part 2): A252, 1999

Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. American Journal of Gastroenterology 95(3): 626-633, 2000

Comparison of Intravenous plus Oral Pantoprazole Therapy and Oral Pantoprazole Alone for Preventing Gastrointestinal Bleeding in Acute Coronary Syndrome Patients with High Bleeding Risk. Heart Lung and Circulation 24(9): 885-890, 2015

Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis. Bmc Gastroenterology 12: 28, 2012